Celldex Therapeutics, Inc.
CLDX
$30.30
$1.766.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -81.32M | -67.04M | -56.60M | -53.80M | -47.09M |
| Total Depreciation and Amortization | 816.00K | 824.00K | 873.00K | 867.00K | 819.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.03M | 7.79M | 7.51M | 7.05M | 6.42M |
| Change in Net Operating Assets | 8.53M | 9.80M | 4.22M | -8.50M | 7.38M |
| Cash from Operations | -63.94M | -48.63M | -44.01M | -54.37M | -32.48M |
| Capital Expenditure | -1.28M | -440.00K | -728.00K | -265.00K | -756.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.71M | 61.29M | 50.58M | 43.22M | 24.80M |
| Cash from Investing | 55.43M | 60.85M | 49.85M | 42.95M | 24.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.35M | 774.00K | 63.00K | 202.00K | 386.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.35M | 774.00K | 63.00K | 202.00K | 386.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.17M | 12.99M | 5.91M | -11.22M | -8.04M |